🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Comparison of olaparib vs. physician's choice of single agent standard of c...
Status
Completed
Location
Research Site
Start Date
2015-02-06
Trial ID
NCT02282020
Treatments Being Tested
Single arm, single site, open-label Phase II study of the effects of oral o...
Status
Recruiting
Location
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Start Date
2019-06-03
Trial ID
NCT03786796
Treatments Being Tested
This is an open-label, single-arm, international, multicenter Multiple Pati...
Status
Approved For Marketing
Location
Research Site
Start Date
TBD
Trial ID
NCT03079687
Treatments Being Tested
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-cont...
Status
Completed
Location
Research Site
Start Date
2017-06-08
Trial ID
NCT03106987
Treatments Being Tested
The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG),...
Status
Unknown
Location
Amsterdam UMC, AMC
Start Date
2019-07-08
Trial ID
NCT03951415
Treatments Being Tested
This is a 2-part study in patients with advanced solid tumours. Part A will...
Status
Completed
Location
Research Site
Start Date
2013-11
Trial ID
NCT01894256
Treatments Being Tested
This study aimed to evaluate the pharmacokinetic characteristics and bioequ...
Status
Completed
Location
The First Affiliated Hospital of Bengbu Medical College
Start Date
2021-05-10
Trial ID
NCT05860530
Treatments Being Tested
Olaparib treatment in patients with germline BRCA1/2 mutations and high ris...
Status
Active Not Recruiting
Location
Research Site
Start Date
2014-04-22
Trial ID
NCT02032823
The trial will compare the drugs olaparib and cediranib with standard chemo...
Status
Completed
Location
Belfast City Hospital
Start Date
2017-03-09
Trial ID
NCT03117933
Treatments Being Tested
The objective of REVOCAN study is to assess the abrogation of PARP inhibito...
Status
Terminated
Location
CHU Jean Minjoz
Start Date
2020-10-05
Trial ID
NCT04826198